Top

Published in:

Open Access 01-10-2018 | Review article

Review of non-clinical risk models to aid prevention of breast cancer

Authors: Kawthar Al-Ajmi, Artitaya Lophatananon, Martin Yuille, William Ollier, Kenneth R. Muir

Published in: Cancer Causes & Control | Issue 10/2018

Abstract

A disease risk model is a statistical method which assesses the probability that an individual will develop one or more diseases within a stated period of time. Such models take into account the presence or absence of specific epidemiological risk factors associated with the disease and thereby potentially identify individuals at higher risk. Such models are currently used clinically to identify people at higher risk, including identifying women who are at increased risk of developing breast cancer. Many genetic and non-genetic breast cancer risk models have been developed previously. We have evaluated existing non-genetic/non-clinical models for breast cancer that incorporate modifiable risk factors. This review focuses on risk models that can be used by women themselves in the community in the absence of clinical risk factors characterization. The inclusion of modifiable factors in these models means that they can be used to improve primary prevention and health education pertinent for breast cancer. Literature searches were conducted using PubMed, ScienceDirect and the Cochrane Database of Systematic Reviews. Fourteen studies were eligible for review with sample sizes ranging from 654 to 248,407 participants. All models reviewed had acceptable calibration measures, with expected/observed (E/O) ratios ranging from 0.79 to 1.17. However, discrimination measures were variable across studies with concordance statistics (C-statistics) ranging from 0.56 to 0.89. We conclude that breast cancer risk models that include modifiable risk factors have been well calibrated but have less ability to discriminate. The latter may be a consequence of the omission of some significant risk factors in the models or from applying models to studies with limited sample sizes. More importantly, external validation is missing for most of the models. Generalization across models is also problematic as some variables may not be considered applicable to some populations and each model performance is conditioned by particular population characteristics. In conclusion, it is clear that there is still a need to develop a more reliable model for estimating breast cancer risk which has a good calibration, ability to accurately discriminate high risk and with better generalizability across populations.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: a cancer. J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107 CrossRef

Li CI (2010) Breast cancer epidemiology. Springer, Berlin. https://doi.org/10.1007/978-1-4419-0685-4 CrossRef

Parkin DM, Fernández LMG (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12:S70–S80. https://doi.org/10.1111/j.1075-122X.2006.00205.x CrossRefPubMed

Schreer I, Lüttges J (2005) Breast cancer: early detection. In: Gourtsoyiannis NC, Ros PR (eds) Radiologic-pathologic correlations from head to toe: understanding the manifestations of disease. Springer, Berlin, pp 767–784. https://doi.org/10.1007/3-540-26664-x_35 CrossRef

Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361(9367):1405–1410. https://doi.org/10.1016/S0140-6736(03)13143-1 CrossRefPubMed

Gotzsche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001877.pub5 CrossRefPubMedPubMedCentral

Anderson BO, Braun S, Lim S, Smith RA, Taplin S, Thomas DB (2003) Early detection of breast cancer in countries with limited resources. Breast J 9(Suppl 2):S51–S59CrossRefPubMed

Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A (2008) Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer 113(8 Suppl):2244–2256. https://doi.org/10.1002/cncr.23842 CrossRefPubMed

Li J, Shao Z (2015) Mammography screening in less developed countries. SpringerPlus 4:615. https://doi.org/10.1186/s40064-015-1394-8 CrossRefPubMedCentralPubMed

10.

Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97(10):715–723. https://doi.org/10.1093/jnci/dji128 CrossRefPubMed

11.

Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A (2012) Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 133(1):1–10. https://doi.org/10.1007/s10549-011-1853-z CrossRefPubMed

12.

National Cancer Institute (2005) The nation’s investment in cancer research. A plan and budget proposal for the fiscal year 2006. https://www.cancer.gov/about-nci/budget/plan/. 2018

13.

Gerds TA, Cai T, Schumacher M (2008) The performance of risk prediction models. Biom J 50(4):457–479. https://doi.org/10.1002/bimj.200810443 CrossRefPubMed

14.

Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW (2010) Assessing the performance of prediction models: a framework for some traditional and novel measures. Epidemiology 21(1):128–138. https://doi.org/10.1097/EDE.0b013e3181c30fb2 CrossRefPubMedCentralPubMed

15.

Moons KG, Altman DG, Vergouwe Y, Royston P (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338:b606. https://doi.org/10.1136/bmj.b606 CrossRefPubMed

16.

Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, Woodward M (2012) Risk prediction models: II. External validation, model updating, and impact assessment. Heart 98(9):691–698. https://doi.org/10.1136/heartjnl-2011-301247 CrossRefPubMed

17.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339. https://doi.org/10.1136/bmj.b2700 CrossRefPubMedPubMedCentral

18.

Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, Hunter DJ (2000) Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 11(6):477–488CrossRefPubMed

19.

Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, Lund E, Adami H-O (2004) A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomark Prev 13(7):1121

20.

Eliassen A, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296(2):193–201. https://doi.org/10.1001/jama.296.2.193 CrossRefPubMed

21.

Folkerd E, Dowsett M (2013) Sex hormones and breast cancer risk and prognosis. Breast 22(Suppl 2):S38–43. https://doi.org/10.1016/j.breast.2013.07.007 CrossRef

22.

Wright CE, Harvie M, Howell A, Evans DG, Hulbert-Williams N, Donnelly LS (2015) Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention. Hereditary Cancer Clin Pract 13(1):1. https://doi.org/10.1186/s13053-014-0023-9 CrossRef

23.

Park B, Ma SH, Shin A, Chang M-C, Choi J-Y, Kim S, Han W, Noh D-Y, Ahn S-H, Kang D (2013) Korean risk assessment model for breast cancer risk prediction. PLoS ONE 8(10):e76736CrossRefPubMedPubMedCentral

24.

Novotny J, Pecen L, Petruzelka L, Svobodnik A, Dusek L, Danes J, Skovajsova M (2006) Breast cancer risk assessment in the Czech female population—an adjustment of the original Gail model. Breast Cancer Res Treat 95(1):29–35CrossRefPubMed

25.

Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364CrossRefPubMed

26.

Win AK, MacInnis RJ, Hopper JL, Jenkins MA (2012) Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomark Prev 21(3):398–410CrossRef

27.

Engel C, Fischer C (2015) Breast cancer risks and risk prediction models. Breast Care 10(1):7–12CrossRefPubMed

28.

Meads C, Ahmed I, Riley R (2012) A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 132(2):365–377. https://doi.org/10.1007/s10549-011-1818-2 CrossRefPubMed

29.

Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R (2008) Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 56(1):45–50CrossRefPubMedPubMedCentral

30.

Emmons KM, Wong MEI, Puleo E, Weinstein N, Fletcher R, Colditz G (2004) Tailored computer-based cancer risk communication: correcting colorectal cancer risk perception. J Health Commun 9(2):127–141. https://doi.org/10.1080/10810730490425295 CrossRefPubMed

31.

Pfeiffer RM, Park Y, Kreimer AR, Lacey JV Jr, Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH (2013) Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 10(7):e1001492CrossRefPubMedPubMedCentral

32.

Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99(23):1782–1792CrossRefPubMed

33.

Lee C, Lee JC, Park B, Bae J, Lim MH, Kang D, Yoo K-Y, Park SK, Kim Y, Kim S (2015) Computational discrimination of breast cancer for Korean women based on epidemiologic data only. J Korean Med Sci 30(8):1025–1034. https://doi.org/10.3346/jkms.2015.30.8.1025 CrossRefPubMedCentralPubMed

34.

Karen ME, Susan K-W, Kathy A, Lisa C, Rima R, Graham C (1999) A qualitative evaluation of the harvard cancer risk index. J Health Commun 4(3):181–193. https://doi.org/10.1080/108107399126904 CrossRef

35.

Bandura A (1992) Exercise of personal agency through the self-efficacy mechanism. In: Self-efficacy: thought control of action. Hemisphere Publishing Corp, Washington, DC, pp 3–38

36.

Lee EO, Ahn SH, You C, Lee DS, Han W, Choe KJ, Noh D-Y (2004) Determining the main risk factors and high-risk groups of breast cancer using a predictive model for breast cancer risk assessment in South Korea. Cancer Nurs 27(5):400–406CrossRefPubMed

37.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886CrossRefPubMed

38.

Ueda K, Tsukuma H, Tanaka H, Ajiki W, Oshima A (2003) Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer 10(1):54–62CrossRefPubMed

39.

Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13(3):183–191CrossRefPubMed

40.

Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA (2012) Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat 132(1):347–353CrossRefPubMed

41.

Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH (2011) Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst 103(12):951–961. https://doi.org/10.1093/jnci/djr154 CrossRefPubMedCentralPubMed

42.

Rosner B, Colditz GA, Willett WC (1994) Reproductive risk factors in a prospective study of breast cancer: the Nurses’ Health Study. Am J Epidemiol 139(8):819–835CrossRefPubMed

43.

Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, Voysey M, Wharton R, Yu LM, Moons KG, Altman DG (2014) External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol 14:40. https://doi.org/10.1186/1471-2288-14-40 CrossRefPubMedCentralPubMed

44.

Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159(9):882–890. https://doi.org/10.1093/aje/kwh101 CrossRefPubMed

45.

Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE (2013) Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 178(2):296–308. https://doi.org/10.1093/aje/kws457 CrossRefPubMedCentralPubMed

46.

Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228CrossRefPubMed

47.

Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115(7):928–935. https://doi.org/10.1161/circulationaha.106.672402 CrossRefPubMed

48.

Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the rancho Bernardo study. J Clin Endocrinol Metab 85(2):645–651. https://doi.org/10.1210/jcem.85.2.6405 CrossRefPubMed

49.

Kim DJ, Rockhill B, Colditz GA (2004) Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk. J Clin Epidemiol 57(4):332–340. https://doi.org/10.1016/j.jclinepi.2003.08.013 CrossRefPubMed

50.

Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152(10):950–964CrossRefPubMed

51.

52.

Emmons KM, Koch-Weser S, Atwood K, Conboy L, Rudd R, Colditz G (1999) A qualitative evaluation of the Harvard Cancer Risk Index. J Health Commun 4(3):181–193. https://doi.org/10.1080/108107399126904 CrossRefPubMed

53.

Pfeiffer RM, Park Y, Kreimer AR, Lacey JV, Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, Hartge P (2013) Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 10(7):e1001492CrossRefPubMedPubMedCentral

54.

Timmers JM, Verbeek AL, IntHout J, Pijnappel RM, Broeders MJ, den Heeten GJ (2013) Breast cancer risk prediction model: a nomogram based on common mammographic screening findings. Eur Radiol 23(9):2413–2419. https://doi.org/10.1007/s00330-013-2836-8 CrossRefPubMed

55.

McCowan C, Donnan PT, Dewar J, Thompson A, Fahey T (2011) Identifying suspected breast cancer: development and validation of a clinical prediction rule. Brit J Gen Pract 61 (586). https://doi.org/10.3399/bjgp11X572391 CrossRef

56.

Cook NR, Rosner BA, Hankinson SE, Colditz GA (2009) Mammographic screening and risk factors for breast cancer. Am J Epidemiol 170(11):1422–1432. https://doi.org/10.1093/aje/kwp304 CrossRefPubMedCentralPubMed

57.

Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148(5):337–375. https://doi.org/10.7326/0003-4819-148-5-200803040-00004 CrossRefPubMedCentralPubMed

58.

Rosner B, Colditz GA, Iglehart JD, Hankinson SE (2008) Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses’ Health Study. Breast Cancer Res 10(4):R55. https://doi.org/10.1186/bcr2110 CrossRefPubMedCentralPubMed

59.

Lee SM, Park JH, Park HJ (2008) Implications of systematic review for breast cancer prediction. Cancer Nurs 31(5):E40–E46. https://doi.org/10.1097/01.NCC.0000305765.34851.e9 CrossRefPubMed

60.

Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA, Women’s Health Initiative I (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99(22):1695–1705. https://doi.org/10.1093/jnci/djm224 CrossRefPubMed

61.

Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: Independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition Cohort. J Natl Cancer I 98(23):1686–1693. https://doi.org/10.1093/jnci/djj463 CrossRef

62.

Chen JB, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer I 98(17):1215–1226. https://doi.org/10.1093/jnci/djj332 CrossRef

63.

Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17):1204–1214. https://doi.org/10.1093/jnci/djj331 CrossRefPubMed

64.

Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR (2005) Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomark Prev 14(2):324–328. https://doi.org/10.1158/1055-9965.EPI-04-0289 CrossRef

65.

Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V (1990) Revisions in the Risk-Based Breast-Cancer Screening-Program at Group Health Cooperative. Cancer 66 (4):812–818. https://doi.org/10.1002/1097-0142(19900815)66:4%3C812::Aid-Cncr2820660436%3E3.0.Co;2-1 CrossRefPubMed

66.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast-cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886. https://doi.org/10.1093/jnci/81.24.1879 CrossRefPubMed

67.

Anderson DE, Badzioch M (1984) Risk of familial breast-cancer. Lancet 1(8373):392–392CrossRefPubMed

68.

Ottman R, Pike MC, King MC, Henderson BE (1983) Practical guide for estimating risk for familial breast-cancer. Lancet 2(8349):556–558CrossRefPubMed

69.

Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC, Modifiers CI, Consortium BCA (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Brit J Cancer 110(2):535–545. https://doi.org/10.1038/bjc.2013.730 CrossRefPubMed

70.

McCarthy AM, Armstrong K, Handorf E, Boghossian L, Jones M, Chen JB, Demeter MB, McGuire E, Conant EF, Domchek SM (2013) Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Res Treat 138(3):889–898. https://doi.org/10.1007/s10549-013-2471-8 CrossRefPubMedCentralPubMed

71.

Dite GS, Mahmoodi M, Bickerstaffe A, Hammet F, Macinnis RJ, Tsimiklis H, Dowty JG, Apicella C, Phillips KA, Giles GG, Southey MC, Hopper JL (2013) Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. Breast Cancer Res Treat 139(3):887–896. https://doi.org/10.1007/s10549-013-2610-2 CrossRefPubMedCentralPubMed

72.

Biswas S, Atienza P, Chipman J, Hughes K, Barrera AMG, Amos CI, Arun B, Parmigiani G (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571–579. https://doi.org/10.1007/s10549-013-2564-4 CrossRefPubMedCentralPubMed

73.

Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y, Tajima K, Tanaka H, Iwata H, Iwase H, Matsuo K (2012) A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 132(2):711–721. https://doi.org/10.1007/s10549-011-1904-5 CrossRefPubMed

74.

Huesing A, Canzian F, Beckmann L, Garcia-Closas M, Diver WR, Thun MJ, Berg CD, Hoover RN, Ziegler RG, Figueroa JD, Isaacs C, Olsen A, Viallon V, Boeing H, Masala G, Trichopoulos D, Peeters PHM, Lund E, Ardanaz E, Khaw KT, Lenner P, Kolonel LN, Stram DO, Le Marchand L, McCarty CA, Buring JE, Lee IM, Zhang SM, Lindstrom S, Hankinson SE, Riboli E, Hunter DJ, Henderson BE, Chanock SJ, Haiman CA, Kraft P, Kaaks R, Bpc3 (2012) Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet 49(9):601–608. https://doi.org/10.1136/jmedgenet-2011-100716 CrossRef

75.

Darabi H, Czene K, Zhao WT, Liu JJ, Hall P, Humphreys K (2012) Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14(1):R25. https://doi.org/10.1186/bcr3110 CrossRefPubMedCentralPubMed

76.

Dai JC, Hu ZB, Jiang Y, Shen H, Dong J, Ma HX, Shen HB (2012) Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res 14(1):R17. https://doi.org/10.1186/bcr3101 CrossRefPubMedCentralPubMed

77.

Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B (2012) Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347–355. https://doi.org/10.1007/s10549-012-1958-z CrossRefPubMed

78.

van Zitteren M, van der Net JB, Kundu S, Freedman AN, van Duijn CM, Janssens ACJW (2011) Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. Cancer Epidem Biomark 20(1):9–22. https://doi.org/10.1158/1055-9965.Epi-10-0329 CrossRef

79.

Crooke PS, Justenhoven C, Brauch H, Dawling S, Roodi N, Higginbotham KSP, Plummer WD, Schuyler PA, Sanders ME, Page DL, Smith JR, Dupont WD, Parl FF, Consortium G (2011) Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction. Cancer Epidemiol Biomark 20(7):1502–1515. https://doi.org/10.1158/1055-9965.Epi-11-0060 CrossRef

80.

Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ (2010) Performance of common genetic variants in breast-cancer risk models. New Engl J Med 362(11):986–993. https://doi.org/10.1056/NEJMoa0907727 CrossRefPubMed

81.

Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PDP, Easton DF (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Brit J Cancer 98(8):1457–1466. https://doi.org/10.1038/sj.bjc.6604305 CrossRefPubMedPubMedCentral

82.

Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130. https://doi.org/10.1002/sim.1668 CrossRefPubMed

83.

Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480. https://doi.org/10.1136/jmg.2003.017996 CrossRefPubMedCentralPubMed

84.

Antoniou AC, Pharoah PPD, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Brit J Cancer 91(8):1580–1590. https://doi.org/10.1038/sj.bjc.6602175 CrossRefPubMedPubMedCentral

85.

Jonker MA, Jacobi CE, Hoogendoorn WE, Nagelkerke NJD, de Bock GH, van Houwelingen JC (2003) Modeling familial clustered breast cancer using published data. Cancer Epidemiol Biomark 12(12):1479–1485

86.

Fisher TJ, Kirk J, Hopper JL, Godding R, Burgemeister FC (2003) A simple tool for identifying unaffected women at a moderately increased or potentially high risk of breast cancer based on their family history. Breast 12(2):120–127. https://doi.org/10.1016/S0960-9776(02)00285-0 CrossRefPubMed

87.

Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL (2003) Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 5(6):R206–R216. https://doi.org/10.1186/bcr644 CrossRefPubMedCentralPubMed

88.

Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490. https://doi.org/10.1200/Jco.20.6.1480 CrossRefPubMed

89.

de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodriguez R, Diaz-Rubio E, Benitez J, Devilee P, Caldes T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing. Int J Cancer 97(4):466–471. https://doi.org/10.1002/ijc.1627 CrossRefPubMed

90.

Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712. https://doi.org/10.1200/Jco.2002.05.121 CrossRefPubMed

91.

Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Brit J Cancer 86(1):76–83. https://doi.org/10.1038/sj/bjc/6600008 CrossRefPubMedPubMedCentral

92.

Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Brit J Cancer 84(5):704–708. https://doi.org/10.1054/bjoc.2000.1626 CrossRefPubMedPubMedCentral

93.

Gilpin CA, Carson N, Hunter AGW (2000) A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 58(4):299–308. https://doi.org/10.1034/j.1399-0004.2000.580408.x CrossRefPubMed

94.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64(4):963–970. https://doi.org/10.1086/302320 CrossRefPubMedCentralPubMed

95.

Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158. https://doi.org/10.1086/301670 CrossRefPubMedCentralPubMed

96.

Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425. https://doi.org/10.1200/Jco.1998.16.7.2417 CrossRefPubMed

97.

Shattuck-Eidens D, Oliphant A, Fau-McClure M, McClure M, Fau-McBride C, McBride C, Fau-Gupte J, Gupte J, Fau-Rubano T, Rubano T, Fau-Pruss D, Pruss D, Fau-Tavtigian SV, Tavtigian SV, Fau-Teng DH, Teng DH, Fau-Adey N, Adey N, Fau-Staebell M, Staebell M, Fau-Gumpper K, Gumpper K, Fau-Lundstrom R, Lundstrom R, Fau-Hulick M, Hulick M, Fau-Kelly M, Kelly M, Fau-Holmen J, Holmen J, Fau-Lingenfelter B, Lingenfelter B, Fau-Manley S, Manley S, Fau-Fujimura F, Fujimura F, Fau-Luce M, Luce M, Fau-Ward B, Ward B, Fau-Cannon-Albright L, Cannon-Albright L, Fau-Steele L, Steele L, Fau-Offit K, Offit K, Fau-Thomas A, Thomas A et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. J Am M Assoc (0098-7484 (Print))

98.

Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL, Jablon L, Cobleigh MA, Hoskins K, Garber JE (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl J Med 336(20):1409–1415. https://doi.org/10.1056/Nejm199705153362002 CrossRefPubMed

99.

Claus EB, Risch N, Thompson WD (1994) Autosomal-dominant inheritance of early-onset breast-cancer—implications for risk prediction. Cancer 73 (3):643–651. https://doi.org/10.1002/1097-0142(19940201)73:3%3C643::Aid-Cncr2820730323%3E3.0.Co;2-5 CrossRefPubMed

100.

Claus EB, Risch N, Thompson WD (1993) The calculation of breast-cancer risk for women with a first degree family history of ovarian-cancer. Breast Cancer Res Treat 28(2):115–120. https://doi.org/10.1007/Bf00666424 CrossRefPubMed

101.

Wang S, Ogundiran T, Ademola A, Olayiwola OA, Adeoye A, Adeniji-Sofoluwe A, Morhason-Bello I, Odedina S, Agwai I, Adebamowo C, Obajimi M, Ojengbede O, Olopade OI, Huo D (2016) Abstract 2590: development and validation of a breast cancer risk prediction model for black women: findings from the Nigerian breast cancer study. Cancer Res. https://doi.org/10.1158/1538-7445.AM2016-2590 CrossRefPubMedCentralPubMed

Title: Review of non-clinical risk models to aid prevention of breast cancer
Authors: Kawthar Al-Ajmi
Artitaya Lophatananon
Martin Yuille
William Ollier
Kenneth R. Muir
Publication date: 01-10-2018
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 10/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-018-1072-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2018

Impact of individual and neighborhood factors on socioeconomic disparities in localized and advanced prostate cancer risk

Intersectional nativity and racial/ethnic disparities in human papillomavirus vaccination initiation among U.S. women: a national population-based study

Effects of program scale-up on time to resolution for patients with abnormal screening mammography results

Racial variation in receipt of quality radiation therapy for prostate cancer

Sleep apnea and subsequent cancer incidence

Indoor tanning and the risk of developing non-cutaneous cancers: a systematic review and meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer